It can be challenging to determine why individual patients respond to the same drug in different manners, with some patients experiencing subtherapeutic responses or unexpected adverse effects to the medications you are prescribing. One of the reasons patients may be experiencing these types of effects is because they aren’t effectively metabolizing the medication due to a genetic polymorphism.
Ameritox has introduced GenetAssistTM, a pharmacogenetic test that can help identify whether your patient metabolizes drugs at a normal rate, a rapid rate, very slowly or not at all. Clinicians can use this data to help determine if they should maintain the current treatment regimen, adjust dose or switch to a different medication in order to optimize patient outcomes. For more information on pharmacogenetic testing or GenetAssist, contact 877-596-2224 or fill out the form to the right.
How can genetic polymorphisms impact
metabolism of medications?
- A family of liver enzymes, the Cytochrome P450 (CYP450) enzymes, are involved in the metabolism of about 90% of all pharmaceutical drugs.
- In addition to evaluating the CYP450 liver enzymes, OPRM1 is also included on our panel. This opioid receptor is a key contributor to inter-individual variability in therapeutic responses to commonly prescribed opioid medications.
- Genetic polymorphisms in CYP450 can affect drug metabolism, causing sub-therapeutic responses and unexpected adverse effects.
- A number of factors can influence a patient’s response to a specific medication. The primary genetic variable to consider is the patient’s phenotype.
Who should be tested?
Testing all patients for genetic polymorphisms is not cost-effective and may not be medically necessary. Clinicians may want to consider pharmacogenetic testing for the following:
- Patients who are currently on a high dose of opioid to control pain and where there is concern regarding use of high-dose opioids.
- Patients who experience unmanageable side effects from their medications.
- Patients that have a suboptimal clinical response to current therapy and the clinician is considering a treatment change.
- Patients who have consistently high or low normalized urine drug levels (Rx Guardian CDSM standard scores consistently below -2 or above +2) and the clinician is trying to evaluate possible non-adherence and metabolism issues.
- Patients who consistently demonstrate abnormal metabolism patterns on urine drug monitoring results (e.g. parent drug found but no metabolite present) and therefore may not be deriving full benefit of prescribed drugs.
How are the results used?
The GenetAssist results report provides relevant and actionable information. Clinicians can use this data to help determine if they should maintain the current treatment regimen, adjust dose or switch to a different medication in order to optimize patient outcomes. Results report includes:
- Important information about whether genetic polymorphisms could be affecting medications prescribed to the patient.
- Detailed genetic results about the patient’s genotypes and phenotypes.
- Information about common medications affected by pathways tested.
Ameritox’s clinical team is available to answer in-depth scientific questions about pharmacogenetics and medication metabolism.
To learn more about Ameritox’s GenetAssist, or how Ameritox can tailor a medication monitoring solution to fit your practice needs, call 877-596-2224 or fill out the form to the right.